Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3069% below fair value
$2.54+0.09 (+3.67%)
Close on Nov 13, 2026Market cap $283.61MP/E 7.3Yield –
Alector r&d expenses
Research and development expenses are spending on new products and technology.
Alector's R&D Expenses for the twelve months ending Sep 30, 2026 was $99.81M, down 27.2% year over year. For fiscal 2025 it was $123.07M, down 33.8% from the year before. The highest annual figure on record is $210.42M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.07M | -33.8% |
| FY2024 | Dec 31, 2024 | $185.94M | -3.2% |
| FY2023 | Dec 31, 2023 | $192.12M | -8.7% |
| FY2022 | Dec 31, 2022 | $210.42M | +11.1% |
| FY2021 | Dec 31, 2021 | $189.41M | +20.7% |
| FY2020 | Dec 31, 2020 | $156.87M | +56.0% |
| FY2019 | Dec 31, 2019 | $100.53M | +37.7% |
| FY2018 | Dec 31, 2018 | $73.03M | +144.2% |
| FY2017 | Dec 31, 2017 | $29.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $30.03M | +2.3% |
| Q2 FY2026 | Jun 30, 2026 | $19.46M | -29.5% |
| Q1 FY2026 | Mar 31, 2026 | $17.86M | -46.9% |
| Q4 FY2025 | Dec 31, 2025 | $32.46M | -30.1% |
| Q3 FY2025 | Sep 30, 2025 | $29.35M | -38.9% |
| Q2 FY2025 | Jun 30, 2025 | $27.61M | -40.4% |
| Q1 FY2025 | Mar 31, 2025 | $33.64M | -25.5% |
| Q4 FY2024 | Dec 31, 2024 | $46.46M | -2.6% |
| Q3 FY2024 | Sep 30, 2024 | $48.00M | +3.6% |
| Q2 FY2024 | Jun 30, 2024 | $46.31M | +0.3% |
| Q1 FY2024 | Mar 31, 2024 | $45.17M | -13.0% |
| Q4 FY2023 | Dec 31, 2023 | $47.72M | -12.4% |
| Q3 FY2023 | Sep 30, 2023 | $46.33M | -4.2% |
| Q2 FY2023 | Jun 30, 2023 | $46.18M | -15.3% |
| Q1 FY2023 | Mar 31, 2023 | $51.89M | -2.2% |
| Q4 FY2022 | Dec 31, 2022 | $54.49M | +3.2% |
| Q3 FY2022 | Sep 30, 2022 | $48.35M | +12.3% |
| Q2 FY2022 | Jun 30, 2022 | $54.53M | +14.0% |
| Q1 FY2022 | Mar 31, 2022 | $53.04M | +16.0% |
| Q4 FY2021 | Dec 31, 2021 | $52.79M | +18.9% |
| Q3 FY2021 | Sep 30, 2021 | $43.07M | -1.7% |
| Q2 FY2021 | Jun 30, 2021 | $47.82M | +40.4% |
| Q1 FY2021 | Mar 31, 2021 | $45.73M | +32.2% |
| Q4 FY2020 | Dec 31, 2020 | $44.38M | +72.3% |
| Q3 FY2020 | Sep 30, 2020 | $43.82M | +53.6% |
| Q2 FY2020 | Jun 30, 2020 | $34.06M | +32.8% |
| Q1 FY2020 | Mar 31, 2020 | $34.61M | +67.9% |
| Q4 FY2019 | Dec 31, 2019 | $25.76M | +6.9% |
| Q3 FY2019 | Sep 30, 2019 | $28.52M | +39.9% |
| Q2 FY2019 | Jun 30, 2019 | $25.64M | +52.5% |
| Q1 FY2019 | Mar 31, 2019 | $20.61M | +75.8% |
| Q4 FY2018 | Dec 31, 2018 | $24.10M | – |
| Q3 FY2018 | Sep 30, 2018 | $20.39M | – |
| Q2 FY2018 | Jun 30, 2018 | $16.82M | – |
| Q1 FY2018 | Mar 31, 2018 | $11.72M | – |
See a number that looks wrong?